Literature DB >> 1929322

Inhibition of Cryptosporidium parvum in neonatal Hsd:(ICR)BR Swiss miceby polyether ionophores and aromatic amidines.

B L Blagburn1, C A Sundermann, D S Lindsay, J E Hall, R R Tidwell.   

Abstract

Cryptosporidicidal effects of two polyether ionophores (maduramicin and alborixin), a fluorinated 4-quinolone (enrofloxacin), and three analogs of pentamidine were evaluated in a suckling mouse bioassay. Treatment with all compounds except enrofloxacin and one of the pentamidine analogs [1,3-di(4-imidazolinophenoxy)propane] resulted in significant (P less than 0.05) reductions in oocyst excretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929322      PMCID: PMC245207          DOI: 10.1128/AAC.35.7.1520

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs.

Authors:  V McDonald; R Stables; D C Warhurst; M R Barer; D A Blewett; H D Chapman; G M Connolly; P L Chiodini; K P McAdam
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

2.  Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  R R Tidwell; S K Jones; J D Geratz; K A Ohemeng; M Cory; J E Hall
Journal:  J Med Chem       Date:  1990-04       Impact factor: 7.446

3.  Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  S K Jones; J E Hall; M A Allen; S D Morrison; K A Ohemeng; V V Reddy; J D Geratz; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Attempted chemoprophylaxis of cryptosporidiosis in calves.

Authors:  H W Moon; G N Woode; F A Ahrens
Journal:  Vet Rec       Date:  1982-02-20       Impact factor: 2.695

5.  Experimental cryptosporidiosis in laboratory mice.

Authors:  D Sherwood; K W Angus; D R Snodgrass; S Tzipori
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

6.  Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis.

Authors:  C A Bell; J E Hall; D E Kyle; M Grogl; K A Ohemeng; M A Allen; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  The species of Cryptosporidium (Apicomplexa: Cryptosporidiidae) infecting mammals.

Authors:  S J Upton; W L Current
Journal:  J Parasitol       Date:  1985-10       Impact factor: 1.276

8.  Cryptosporidiosis in homosexual men.

Authors:  R Soave; R L Danner; C L Honig; P Ma; C C Hart; T Nash; R B Roberts
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

9.  The therapeutic effect of 16 antimicrobial agents on Cryptosporidium infection in mice.

Authors:  S R Tzipori; I Campbell; K W Angus
Journal:  Aust J Exp Biol Med Sci       Date:  1982-04

10.  Characterization of cyclophosphamide-rat model of cryptosporidiosis.

Authors:  J E Rehg; M L Hancock; D B Woodmansee
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

View more
  11 in total

1.  Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum.

Authors:  M E Perkins; T W Wu; S M Le Blancq
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia.

Authors:  R R Tidwell; S K Jones; N A Naiman; L C Berger; W B Brake; C C Dykstra; J E Hall
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

3.  Anti-Pneumocystis activities of aromatic diamidoxime prodrugs.

Authors:  J E Hall; J E Kerrigan; K Ramachandran; B C Bender; J P Stanko; S K Jones; D A Patrick; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model.

Authors:  B L Blagburn; K L Drain; T M Land; R G Kinard; P H Moore; D S Lindsay; D A Patrick; D W Boykin; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

5.  Polyether ionophores: broad-spectrum and promising biologically active molecules for the control of drug-resistant bacteria and parasites.

Authors:  Dion A Kevin Ii; Damaris Af Meujo; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2009-02       Impact factor: 6.098

6.  Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice.

Authors:  M W Riggs; V A Cama; H L Leary; C R Sterling
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells.

Authors:  C C Dykstra; D R McClernon; L P Elwell; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 8.  Novel amidines and analogues as promising agents against intracellular parasites: a systematic review.

Authors:  M N C Soeiro; K Werbovetz; D W Boykin; W D Wilson; M Z Wang; A Hemphill
Journal:  Parasitology       Date:  2013-04-08       Impact factor: 3.234

9.  Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents.

Authors:  M Del Poeta; W A Schell; C C Dykstra; S Jones; R R Tidwell; A Czarny; M Bajic; A Kumar; D Boykin; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis.

Authors:  J R Mead; X You; J E Pharr; Y Belenkaya; M J Arrowood; M T Fallon; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.